Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity In human malignant glioma cells

International Journal of Cancer

Volumn 124, Issue 5, 2009, Pages 1060-1071

  Shimgu, Takashi ^a   Fujiwara, Keishi ^a   Bogler, Oliver ^a   Akiyama, Yasuhiko ^b   Meritake, Kouzo ^b   Shinojima, Naoki ^a   Tamacla, Yutaka ^a   Yokoyama, Tomohisa ^a   Kondo, Seiji ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Autophogy; Bafilomycin Al; Imatinib; Malignant glomia; RTA 203

Indexed keywords

3 METHYLADENINE; BAFILOMYCIN A1; IMATINIB; MICROTUBULE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN ATG5; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3-METHYLADENINE; ADENINE; ANTINEOPLASTIC AGENT; ATG5 PROTEIN, HUMAN; CISPLATIN; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; MACROLIDE; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RTA 203;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DAMAGE; CELL DEATH; CELL DISRUPTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BRAIN TUMOR; DRUG ANTAGONISM; GLIOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENINE; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOMA; HUMANS; MACROLIDES; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROTUBULE-ASSOCIATED PROTEINS; PACLITAXEL; PIPERAZINES; PYRIMIDINES;

EID: 58749088233     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24030     Document Type: Article

References (20)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Halm WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710.
2. Wen PY, Yung WKA, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-907.
3. Storarnel JM, Kimraelraan AC, Ying H, Nabioullin R, Ponngoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-66.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
6. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfie V, Duyster J, Elsasser HP, Schätzl HM. Tfhe anticancer drug imatinib induces cellular autophagy. Leukemia 2007;21:936-42.
7. Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kasteraar M, Heldin CH, Isaksson A, Nistér M, Östman A. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006;25:4913-22.
8. Kilic T, Alberta JA, Zdunek PR, Acar M, lannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyriraidine class. Cancer Res 2000;60:5143-50.
9. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vreden-burgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, et al. Phase II study of imatinib mesvlate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9359-68.
10. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717-21.
11. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
12. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008; 90:313-23.
13. Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. Autophagy 2007;3:181-206.
14. Amenta JS, Sargus MJ, Baccino FM. Effect of raicrotubular or transla-tional inhibitors on general cell protein degradation. Biochem J 1977; 168:223-27.
15. Punnonen EL, Reunanen H. Effects of vinblastine, leucine, and histi-dine, and 3-methvladenine on autophagy in Ehrlich ascites cells. Exp Mol Pathol 1990;52:87-97.
16. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomyein Al prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line. H-4-II-E cells. Cell Struct Fund 1998; 23:33-42.
17. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11:448-57.
18. Boya P, González-Polo RA, Casares N, Perfettini JL, Dessen P, Lar-ochette N, Métivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codongno P. et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005;25:1025-40.
19. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115:2679-88.
20. Katayama M, Kawaguchi T, Berger MS, Pieper RO. DNA-damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007; 14: 548-58.